{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,9]],"date-time":"2026-10-09T18:04:54Z","timestamp":1791569094610,"version":"4.3.4"},"reference-count":30,"publisher":"Wiley","issue":"6","license":[{"start":{"date-parts":[[2026,2,23]],"date-time":"2026-02-23T00:00:00Z","timestamp":1771804800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"},{"start":{"date-parts":[[2026,2,23]],"date-time":"2026-02-23T00:00:00Z","timestamp":1771804800000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/doi.wiley.com\/10.1002\/tdm_license_1.1"}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Int J Dermatology"],"published-print":{"date-parts":[[2026,6]]},"abstract":"<jats:title>ABSTRACT<\/jats:title>\n                  <jats:sec>\n                    <jats:label\/>\n                    <jats:p>Hidradenitis suppurativa (HS) is a chronic inflammatory skin disease closely associated with obesity and metabolic dysfunction, which contribute to increased disease severity, reduced treatment response, and impaired quality of life. Incretin\u2010based therapies, including glucagon\u2010like peptide\u20101 receptor agonists (GLP\u20101 RAs) and dual glucose\u2010dependent insulinotropic polypeptide (GIP)\/GLP\u20101 receptor agonists, are increasingly used for obesity and metabolic disease, prompting interest in their potential adjunctive role in HS management. To synthesize the available human evidence on the use of incretin\u2010based therapies in patients with HS, focusing on clinical outcomes, weight change, and patient\u2010reported measures. A narrative review of the published literature was conducted using major medical databases. Eligible publications included case reports, case series, and observational studies reporting HS outcomes in patients treated with GLP\u20101 RAs or dual GIP\/GLP\u20101 receptor agonists. Findings were summarized descriptively and interpreted in the context of metabolic modulation. The current evidence base consists predominantly of case\u2010level reports and a limited number of observational cohorts. Across studies, incretin\u2010based therapies were associated with significant weight loss and concurrent improvements in HS disease activity, flare frequency, pain, and quality of life. Improvements in HS outcomes generally paralleled weight reduction, suggesting that metabolic effects play a primary role. Evidence supporting weight\u2010independent anti\u2010inflammatory effects remains limited and inconclusive. Incretin\u2010based therapies appear to offer potential benefit as metabolic adjuncts in HS, particularly for patients with coexisting obesity or metabolic syndrome. However, available data are observational and hypothesis\u2010generating. Prospective controlled studies are required to clarify mechanisms, identify optimal patient populations, and define the role of incretin\u2010based therapies within comprehensive HS management.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1111\/ijd.70346","type":"journal-article","created":{"date-parts":[[2026,3,8]],"date-time":"2026-03-08T08:10:26Z","timestamp":1772957426000},"page":"1168-1175","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["Glucagon\u2010Like Peptide\u20101 Receptor Agonists as Adjunctive Therapy for Hidradenitis Suppurativa in Patients With Overweight\/Obesity: A Narrative Review of Efficacy, Safety, and Quality\u2010of\u2010Life Outcomes"],"prefix":"10.1111","volume":"65","author":[{"given":"Eman","family":"Almukhadeb","sequence":"first","affiliation":[{"name":"Department of Dermatology, College of Medicine King Saud University  Riyadh Saudi Arabia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0008-6577-6463","authenticated-orcid":false,"given":"Khalid Nabil","family":"Nagshabandi","sequence":"additional","affiliation":[{"name":"Department of Dermatology, College of Medicine King Saud University  Riyadh Saudi Arabia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Naif","family":"Alshehri","sequence":"additional","affiliation":[{"name":"Department of Dermatology, College of Medicine King Saud University  Riyadh Saudi Arabia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0007-4257-7544","authenticated-orcid":false,"given":"Khalid","family":"Alosaimi","sequence":"additional","affiliation":[{"name":"Division of Plastic Surgery, Department of Surgery, King Abdulaziz Medical City, Ministry of National Guard\u2010Health Affairs (MNG\u2010HA) King Abdullah International Medical Research Center (KAIMRC)  Riyadh Saudi Arabia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hala Abdullah","family":"Almusa","sequence":"additional","affiliation":[{"name":"Department of Dermatology and Allergy, Clinical Research Center for Hair and Skin Science Charit\u00e9\u2010Universit\u00e4tsmedizin  Berlin Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Almuntsrbellah","family":"Almudimeegh","sequence":"additional","affiliation":[{"name":"Department of Dermatology, College of Medicine King Saud University  Riyadh Saudi Arabia"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2026,2,23]]},"reference":[{"key":"e_1_2_9_2_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41572-020-0149-1"},{"key":"e_1_2_9_3_1","doi-asserted-by":"publisher","DOI":"10.3390\/cells10082094"},{"key":"e_1_2_9_4_1","doi-asserted-by":"publisher","DOI":"10.1007\/s13555\u2010023\u201001085\u2010w"},{"key":"e_1_2_9_5_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.adengl.2019.03.017"},{"key":"e_1_2_9_6_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00403\u2010024\u201003762\u2010y"},{"key":"e_1_2_9_7_1","doi-asserted-by":"publisher","DOI":"10.5603\/FD.104845"},{"key":"e_1_2_9_8_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40257\u2010024\u201000911\u2010x"},{"key":"e_1_2_9_9_1","doi-asserted-by":"publisher","DOI":"10.3390\/jcm13216292"},{"key":"e_1_2_9_10_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2032183"},{"key":"e_1_2_9_11_1","doi-asserted-by":"publisher","DOI":"10.1007\/s13671\u2010025\u201000481\u2010z"},{"key":"e_1_2_9_12_1","doi-asserted-by":"publisher","DOI":"10.1111\/bjd.15233"},{"key":"e_1_2_9_13_1","doi-asserted-by":"publisher","DOI":"10.1159\/000473873"},{"key":"e_1_2_9_14_1","doi-asserted-by":"publisher","DOI":"10.1111\/bjd.15742"},{"key":"e_1_2_9_15_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2023.07.359"},{"key":"e_1_2_9_16_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jdcr.2024.02.023"},{"key":"e_1_2_9_17_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.medcli.2023.11.007"},{"key":"e_1_2_9_18_1","doi-asserted-by":"publisher","DOI":"10.1111\/jdv.20392"},{"key":"e_1_2_9_19_1","doi-asserted-by":"publisher","DOI":"10.1093\/bjd\/ljae216"},{"key":"e_1_2_9_20_1","doi-asserted-by":"publisher","DOI":"10.1111\/ijd.70191"},{"key":"e_1_2_9_21_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.eclinm.2022.101737"},{"key":"e_1_2_9_22_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jcte.2024.100340"},{"issue":"9","key":"e_1_2_9_23_1","first-page":"34","article-title":"The Use of GLP\u20101 Agonists in the Management of Cutaneous Disease","volume":"17","author":"Lal K.","year":"2024","journal-title":"Journal of Clinical and Aesthetic Dermatology"},{"key":"e_1_2_9_24_1","doi-asserted-by":"publisher","DOI":"10.1177\/1203475419874412"},{"key":"e_1_2_9_25_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40257-023-00756-w"},{"key":"e_1_2_9_26_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jdcr.2023.01.035"},{"key":"e_1_2_9_27_1","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2025.1627638"},{"key":"e_1_2_9_28_1","doi-asserted-by":"publisher","DOI":"10.1111\/jdv.20694"},{"key":"e_1_2_9_29_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00228\u2010025\u201003898\u20104"},{"issue":"11","key":"e_1_2_9_30_1","first-page":"1026","article-title":"A Closer Look at the Dermatological Profile of GLP\u20101 Agonists","volume":"23","author":"Vidal S. I.","year":"2024","journal-title":"Journal of Drugs in Dermatology"},{"key":"e_1_2_9_31_1","doi-asserted-by":"publisher","DOI":"10.1093\/bjd\/ljaf346"}],"container-title":["International Journal of Dermatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/ijd.70346","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1111\/ijd.70346","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/ijd.70346","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,20]],"date-time":"2026-07-20T09:59:13Z","timestamp":1784541553000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/ijd.70346"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,2,23]]},"references-count":30,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2026,6]]}},"alternative-id":["10.1111\/ijd.70346"],"URL":"https:\/\/doi.org\/10.1111\/ijd.70346","archive":["Portico"],"relation":{},"ISSN":["0011-9059","1365-4632"],"issn-type":[{"value":"0011-9059","type":"print"},{"value":"1365-4632","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,2,23]]},"assertion":[{"value":"2025-12-22","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-02-06","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-02-23","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}